文献速递胸部肿瘤

低DLL3表达与T细胞耗竭驱动SCLC对塔拉妥单抗联合抗PD-1耐药

Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti-Programmed Cell Death Protein 1 in SCLC.
PubMed 文献 · J Thorac Oncol · 2026-03-27

本文通过两例广泛期小细胞肺癌患者的肿瘤活检样本,分析了塔拉妥单抗联合抗PD-1治疗前后肿瘤微环境的变化。耐药后标本显示肿瘤细胞DLL3表达降低、形态向非小细胞肺癌样转变,且耗竭CD8+ T细胞及免疫抑制细胞显著增多。提示低DLL3表达和免疫抑制微环境与获得性耐药相关。

要点

  • 耐药后肿瘤细胞DLL3表达降低,伴形态向NSCLC样转变。
  • 耐药后微环境中耗竭CD8+ T细胞及免疫抑制细胞显著增多。
  • 联合免疫检查点阻断或髓系靶向治疗可能改善疗效。

核心结论

  • SCLC对塔拉妥单抗联合抗PD-1的获得性耐药与低DLL3抗原表达、NSCLC样形态转变及免疫抑制性肿瘤微环境相关。

研究设计与样本

  • 对2例接受塔拉妥单抗联合抗PD-1抗体治疗的广泛期SCLC患者(1b期临床试验,jRCT: 2051240045)进行基线及进展时肿瘤活检样本的多重免疫组化分析。

主要发现

  • 耐药后标本显示两例均出现肿瘤细胞表型转变,胞质丰富且突触素表达降低。
  • 进展时肿瘤细胞DLL3表达低。
  • 进展时肿瘤微环境中表达PD-1、TIGIT、LAG-3的耗竭CD8+ T细胞及CTLA-4调节性T细胞、CD206+ M2肿瘤相关巨噬细胞较治疗前显著增多。

临床怎么用

  • 对塔拉妥单抗联合抗PD-1耐药的小细胞肺癌患者,可考虑联合免疫检查点阻断或髓系靶向治疗策略。

局限性

  • 仅基于2例患者的活检样本分析,样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: SCLC is an aggressive malignancy with poor prognosis. Tarlatamab, a bispecific T-cell engager that targets CD3 and delta-like ligand 3 (DLL3), is the standard of care for patients with previously treated SCLC. However, the mechanisms underlying acquired tarlatamab resistance remain unclear. METHODS: We assessed two patients with extensive-stage SCLC treated with tarlatamab and an anti-programmed cell death protein 1 (PD-1) antibody in a phase 1b clinical trial (jRCT: 2051240045). We analyzed tumor biopsy samples obtained at baseline and at time of progressive disease using multiplexed immunohistochemistry. RESULTS: Pathologic analysis of post-resistance specimens revealed a phenotypic shift in both cases, characterized by tumor cells with abundant cytoplasm and reduced synaptophysin expression levels. Multiplexed immunohistochemistry revealed low DLL3 expression on tumor cells at time of progression. In addition, exhausted CD8+ T cells expressing PD-1+, T-cell immunoreceptor with Ig and ITIM domains, lymphocyte-activation gene 3, and immunosuppressive cells, including cytotoxic T-lymphocyte-associated protein 4 regulatory T cells and CD206+ M2 tumor-associated macrophages, were significantly more abundant in the tumor microenvironment than that in samples obtained before tarlatamab plus anti-PD-1 combination therapy. CONCLUSIONS: Acquired resistance to tarlatamab plus anti-PD-1 in SCLC was associated with low DLL3 antigen expression particularly in the setting of phenotypic switch to an NSCLC morphology and an increasingly immunosuppressive tumor microenvironment. Therefore, combination strategies that incorporate immune checkpoint blockade or myeloid-targeted therapies may be warranted to enhance treatment outcomes.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Fukuda A, Fukami T, Nomura K, et al. Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti-Programmed Cell Death Protein 1 in SCLC. J Thorac Oncol. 2026. PMID: 41903703. doi:10.1016/j.jtho.2026.103693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。